This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.
Additional locations may be listed on ClinicalTrials.gov for NCT05502523.
Locations matching your search criteria
United States
Pennsylvania
Abington
Jefferson Abington HospitalStatus: Active
Contact: Tyler Grenda
Phone: 215-955-6996
Philadelphia
Jefferson Torresdale HospitalStatus: Active
Contact: Tyler Grenda
Phone: 215-955-6996
Thomas Jefferson University HospitalStatus: Active
Contact: Tyler Grenda
Phone: 215-955-5562
PRIMARY OBJECTIVE:
I. To determine the association between sequence of surgical resection and postoperative ctDNA levels at specified time points.
SECONDARY OBJECTIVE:
I. To determine the associated between sequence of surgical resection and postoperative ctDNA level and clinical oncologic outcomes.
II. To assess disease-free survival and the role of circulating tumor DNA in disease recurrence in patients with resectable non-small cell lung cancer.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients undergo pulmonary vein first approach surgical procedure on day of surgery. Patients also undergo blood sample collection on study.
GROUP II: Patients undergo pulmonary artery first approach surgical procedure on day of surgery. Patients also undergo blood sample collection on study.
After completion of surgery, patients are followed up at days 1, 7-28, 4 months, every 6 months for 2 years, then every 6 months for up to 5 years
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationThomas Jefferson University Hospital
Principal InvestigatorTyler Grenda
